The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439

Macrophage Diversity Enhances Tumor Progression and Metastasis

Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,338

The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited

Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686

Alternative activation of macrophages: mechanism and functions

Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089

Clonal heterogeneity and tumor evolution: past, present, and the future

McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290

Distinct role of macrophages in different tumor microenvironments

Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225

Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide

Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H.-L., Steinman, R. M., & Choi, Y. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2075 · Cited by 853

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 672

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599

Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage Polarization

Sicco, C. L., Reverberi, D., Balbi, C., Ulivi, V., Principi, E., Pascucci, L., Becherini, P., Bosco, M. C., Varesio, L., Franzin, C., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.16-0363 · Cited by 579

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 560

Cancer stem cell niche: the place to be

Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508

Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling

Guihard, P. J., Danger, Y., Royer, B. B.-L., David, E., Brion, R., Delécrin, J., Richards, C. D., Chevalier, S., Rédiní, F., Heymann, D., et al. (2012) · Stem Cells · doi:10.1002/stem.1040 · Cited by 477

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466

Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts

Hoffman, R. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3972 · Cited by 424

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353

The B7 Family and Cancer Therapy: Costimulation and Coinhibition

Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 340

The biology of normal bone remodelling

Katsimbri, P. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12740 · Cited by 340

Mechanisms of bone repair and regeneration

Deschaseaux, F., Sensebé, L., & Heymann, D. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.002 · Cited by 330

Cancer stem cells in osteosarcoma

Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267

Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?

Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233

Bone microenvironment signals in osteosarcoma development

Alfranca, A., Martínez-Cruzado, L., Tornín, J., Abarrategi, A., Amaral, A. T., de Álava, E., Menéndez, P. R., Garcı́a-Castro, J., & Rodrı́guez, R. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1918-y · Cited by 224

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215

Osteoclastic acidification pathways during bone resorption

Rousselle, A. V., & Heymann, D. (2002) · Bone · doi:10.1016/s8756-3282(02)00672-5 · Cited by 210

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D. C., Schwab, J. H., Nielsen, G. P., Chebib, I. A., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 200

Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment

Ségaliny, A. I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson‐Vidal, C., & Heymann, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29376 · Cited by 199

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197

Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment

Zachar, L., Bačenková, D., & Rosocha, J. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s121994 · Cited by 191

Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression

Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187

Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma

Dumars, C., Ngyuen, J.-M., Gaultier, A., Lanel, R., Corradini, N., Gouin, F., Heymann, D., & Heymann, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13055 · Cited by 183

B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis

Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070689 · Cited by 178

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

Baud’huin, M., Lamoureux, F., Duplomb, L., Rédiní, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 177

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

Krishnadas, D. K., Shusterman, S., Bai, F., Diller, L., Sullivan, J. E., Cheerva, A. C., George, R. E., & Lucas, K. G. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1731-3 · Cited by 176

RANK–RANKL signalling in cancer

Renema, N., Navet, B., Heymann, M., Lézot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 171

Macrophages and skeletal health

Michalski, M. N., & McCauley, L. K. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.017 · Cited by 171

Mesenchymal stroma: Role in osteosarcoma progression

Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171

All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages

Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., Cao, J., Yang, X., Yang, B., Ying, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0259 · Cited by 168

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

Jespersen, H., Lindberg, M. F., Donia, M., Forsberg, E. M. V., Andersen, R. S., Keller, U. B., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 161

Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis

Baud’huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., Gouin, F., Duplomb, L., & Heymann, D. (2010) · The Journal of Pathology · doi:10.1002/path.2684 · Cited by 160

Multimodal transfer of MDR by exosomes in human osteosarcoma

Torreggiani, E., Roncuzzi, L., Perut, F., Zini, N., & Baldini, N. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3509 · Cited by 157

CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma

Han, Q., Shi, H., & Liu, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.023 · Cited by 153

Mifamurtide for the treatment of nonmetastatic osteosarcoma

Ando, K., Mori, K., Corradini, N., Rédiní, F., & Heymann, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.543129 · Cited by 144

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations

Bousquet, M., Noirot, C., Accadbled, F., de Gauzy, J. S., Castex, M., Brousset, P., & Gomez‐Brouchet, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw009 · Cited by 143

CD8 + /FOXP3 + -ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study

Fritzsching, B., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 140

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma

Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157176 · Cited by 140

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

Heymann, D., Ory, B., Gouin, F., Green, J. R., & Rédiní, F. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.05.007 · Cited by 139

Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation

Avnet, S., Pompo, G. D., Chano, T., Errani, C., Ibrahim‐Hashim, A., Gillies, R. J., Donati, D. M., & Baldini, N. (2016) · International Journal of Cancer · doi:10.1002/ijc.30540 · Cited by 137

Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer

Foppen, M. H. G., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 133

Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad

Mohseny, A. B., & Hogendoorn, P. C. W. (2011) · Stem Cells · doi:10.1002/stem.596 · Cited by 125

Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence

Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120

Inflammatory Osteoclasts Prime TNFα-Producing CD4+ T Cells and Express CX3CR1

Ibáñez, L., Abou-Ezzi, G., Ciucci, T., Amiot, V., Belaïd, N., Obino, D., Mansour, A., Rouleau, M., Wakkach, A., & Blin-Wakkach, C. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2868 · Cited by 117

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy

Sundara, Y. T., Kostine, M., Cleven, A. H. G., Bovée, J. V. M. G., Schilham, M. W., & Cleton-Jansen, A.-M. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1925-3 · Cited by 111

The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis

Endo‐Munoz, L., Evdokiou, A., & Saunders, N. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.003 · Cited by 108

Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells

Kimura, Y., & Sumiyoshi, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.048 · Cited by 104

Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation

Muthana, M., Rodrigues, S., Chen, Y., Welford, A. F., Hughes, R., Tazzyman, S. J., Essand, M., Morrow, F. J., & Lewis, C. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3056 · Cited by 104

Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion

Cortini, M., Massa, A., Avnet, S., Bonuccelli, G., & Baldini, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166500 · Cited by 102

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

Pahl, J. H. W., Kwappenberg, K. M. C., Varypataki, E. M., Santos, S. J., Kuijjer, M. L., Mohamed, S., Wijnen, J., van Tol, M. J. D., Cleton-Jansen, A., Egeler, R. M., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-27 · Cited by 101

Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma

Biller, B. J., Guth, A., Burton, J. H., & DOW, S. W. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0557.x · Cited by 100

Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B

Mori, K., Goff, B. L., Berreur, M., Riet, A. V., Moreau, A., Blanchard, F., Chevalier, C., Guisle, I., Leger, J. J., Guicheux, J., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2140 · Cited by 99

γδ T Cells: Unexpected Regulators of Cancer Development and Progression

Fleming, C., Morrissey, S. M., Cai, Y., & Yan, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.06.003 · Cited by 97

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 95

Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3

Tu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent

van Erp, A. E. M., Versleijen‐Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., van Houdt, L., Gorris, M. A. J., van Dam, L. S., Mentzel, T., Weidema, M. E., Savci-Heijink, C. D., Desar, I. M. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19071 · Cited by 92

RANKL blockade prevents and treats aggressive osteosarcomas

Chen, Y., Grappa, M. A. D., Molyneux, S. D., McKee, T. D., Waterhouse, P. D., Penninger, J. M., & Khokha, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0295 · Cited by 90

Mesenchymal Stem/Stromal Cells under Stress Increase Osteosarcoma Migration and Apoptosis Resistance via Extracellular Vesicle Mediated Communication

Vallabhaneni, K. C., Hassler, M.-Y., Abraham, A., Whitt, J. D., Mo, Y., Atfi, A., & Pochampally, R. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166027 · Cited by 90

Prognostic value of inflammation-based scores in patients with osteosarcoma

Liu, B., Huang, Y., Sun, Y., Zhang, J., Yao, Y., Shen, Z., Xiang, D., & He, A. (2016) · Scientific Reports · doi:10.1038/srep39862 · Cited by 89

Increased osteoclast activity is associated with aggressiveness of osteosarcoma

Avnet, S. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000113 · Cited by 84

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Fernández, L., Valentín, J., Zalacaín, M., Leung, W. H., Patiño‐García, A., & Pérez‐Martínez, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.042 · Cited by 77

Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma

Théoleyre, S., Mori, K., Cherrier, B., Passuti, N., Gouin, F., Rédiní, F., & Heymann, D. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-123 · Cited by 75

Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours

Inagaki, Y., Hookway, E. S., Williams, K., Hassan, A. B., Oppermann, U. C. T., Tanaka, Y., Soilleux, E. J., & Athanasou, N. A. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0053-3 · Cited by 72

Osteosarcoma: Current status of immunotherapy and future trends (Review)

Mori, K., Rédiní, F., Gouin, F., Cherrier, B., & Heymann, D. (2006) · Oncology Reports · doi:10.3892/or.15.3.693 · Cited by 69

Canonical and non-canonical pathways of osteoclast formation.

Knowles, H. J., & Athanasou, N. A. (2009) · PubMed · doi:10.14670/hh-24.337 · Cited by 67

Drugs in early clinical development for the treatment of osteosarcoma

Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 65

Pre‐operative lymphocyte‐to‐monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma

Liu, T., Fang, X.-C., Ding, Z., Sun, Z.-G., Sun, L.-M., & Wang, Y.-L. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.08.002 · Cited by 64

Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients

Hingorani, P., Maas, M. L., Gustafson, M. P., Dickman, P. S., Adams, R. H., Watanabe, M., Eshun, F., Williams, J., Seidel, M. J., & Dietz, A. B. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0082-0 · Cited by 62

Expression of programmed death 1 is correlated with progression of osteosarcoma

Zheng, W., Xiao, H. P., Liu, H., & Zhou, Y. (2014) · Apmis · doi:10.1111/apm.12311 · Cited by 60

IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway

Li, Z., Xu, Q., Peng, H., Cheng, R.-L., Sun, Z., & Ye, Z. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.001 · Cited by 59

Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors

Pinto, N. R., Park, J. R., Murphy, E., Yearley, J. H., McClanahan, T., Annamalai, L., Hawkins, D. S., & Rudzinski, E. R. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26613 · Cited by 57

Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug

Murakami, T., Igarashi, K., Kawaguchi, K., Kiyuna, T., Zhang, Y., Zhao, M. D., Hiroshima, Y., Nelson, S. D., Dry, S., Li, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14040 · Cited by 56

Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients

Li, X., Chen, Y., Liu, X., Zhang, J. C., Xu, H., Teng, G., & Yu, D. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.006 · Cited by 56

Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway

Wang, Y., Chu, Y., Yue, B., Ma, X., Zhang, G., Xiang, H., Liu, Y., Wang, T., Wu, X., & Chen, B. (2017) · Oncotarget · doi:10.18632/oncotarget.15866 · Cited by 56

Intra-arterial administration of tumor-targetingSalmonella typhimuriumA1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model

Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., Russell, T. A., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317417 · Cited by 54

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology

Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., Nelson, S. D., Dry, S., Li, Y., Yanagawa, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19095 · Cited by 54

Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype

Rivoltini, L., Arienti, F., Orazi, A., Cefalo, G., Gasparini, M., Gambacorti-Passerini, C. B., Fossati‐Bellani, F., & Parmiani, G. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741792 · Cited by 53

Establishment of a patient-derived orthotopic osteosarcoma mouse model

Blattmann, C., Thiemann, M., Stenzinger, A., Roth, E. K., Dittmar, A., Witt, H., Lehner, B., Renker, E. K., Jugold, M., Eichwald, V., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0497-x · Cited by 51

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma

Kawano, M., Itonaga, I., Iwasaki, T., Tsuchiya, H., & Tsumura, H. (2012) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-012-2299-2 · Cited by 51

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis

Zhu, Z., Jin, Z., Zhang, M., Tang, Y., Yang, G., Yuan, X., Yao, J., & Sun, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19168 · Cited by 45

Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats

Chauvin, C., Philippeau, J.-M., Hémont, C., Hubert, F., Wittrant, Y., Lamoureux, F., Trinité, B., Heymann, D., Rédiní, F., & Josien, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0104 · Cited by 43

RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward?

Cathomas, R. L., Rothermundt, C. A., Bode, B., Fuchs, B., von Moos, R., & Schwitter, M. (2014) · Oncology · doi:10.1159/000369975 · Cited by 42

Invariant NKT cells increase drug‐induced osteosarcoma cell death

Fallarini, S., Paoletti, T., Battaglini, N. O., & Lombardi, G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02108.x · Cited by 40

Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis

Guma, S. R., Lee, D. A., Yu, L., Gordon, N. B., & Kleinerman, E. S. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25019 · Cited by 40

Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models

Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédiní, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 40

Sensitization of human osteosarcoma cells to Vγ9Vδ2 T‐cell‐mediated cytotoxicity by zoledronate

Li, Z., Peng, H., Xu, Q., & Ye, Z. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.21579 · Cited by 40

Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells

Muraro, M., Mereuta, O. M., Carraro, F., Madon, E., & Fagioli, F. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2007.11.005 · Cited by 38

Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion

Yu, F., Hu, W., He, B., Zheng, Y., Zhang, Q., & Chen, L. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0465-1 · Cited by 38

Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma

KAWANO, M., TANAKA, K., ITONAGA, I., IWASAKI, T., MIYAZAKI, M., IKEDA, S., & TSUMURA, H. (2015) · Oncology Reports · doi:10.3892/or.2015.4161 · Cited by 38

Mast cells in atherosclerosis as a source of the cytokine RANKL

Ali, A. S., Lax, A.-S., Liljeström, M., Paakkari, I., Ashammakhi, N. A., Kovanen, P. T., & Konttinen, Y. T. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.117 · Cited by 37

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases

Mori, K., Ando, K., & Heymann, D. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.151 · Cited by 37

Potential of human γδ T cells for immunotherapy of osteosarcoma

Li, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2077-y · Cited by 34

Natural Killer Cells for Osteosarcoma

Tarek, N., & Lee, D. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_19 · Cited by 32

Patient-Derived Mouse Models of Cancer

Hoffman, R. M. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0 · Cited by 31

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

Kunz, P., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Ruef, P., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4001-2 · Cited by 29

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics

Guilhamon, P., Butcher, L. M., Presneau, N., Wilson, G. A., Feber, A., Paul, D. S., Schütte, M., Haybaeck, J., Keilholz, U., Hoffman, J., et al. (2014) · Genome Medicine · doi:10.1186/s13073-014-0116-0 · Cited by 27

Bone sarcomas: pathogenesis and new therapeutic approaches

Heymann, D., & Rédiní, F. (2011) · IBMS BoneKEy · doi:10.1138/20110531 · Cited by 26

Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization

Benslimane-Ahmim, Z., Pereira, J. R. D. S., Lokajczyk, A., Dizier, B., Galy–Fauroux, I., Fischer, A., Heymann, D., & Boisson‐Vidal, C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.032 · Cited by 25

In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma

He, Y.-T., Zhang, Q.-M., Kou, Q.-C., & Tang, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4714 · Cited by 22

Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice

Yin, S. J., Wang, W., & Zhang, J. Y. (2015) · Genetics and Molecular Research · doi:10.4238/2015.november.13.9 · Cited by 20

Genetically Modified T-Cell Therapy for Osteosarcoma

DeRenzo, C. C., & Gottschalk, S. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_18 · Cited by 18

Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells

Liu, M., Sun, L., Li, Y., Li, H., Zhang, J., Li, B., & Ye, Z. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.002 · Cited by 17

Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response

Fang, X., Jiang, C., & Xia, Q. (2015) · Genetics and Molecular Research · doi:10.4238/2015.october.2.10 · Cited by 16

Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip

Tellez-Gabriel, M., Charrier, C., Brounais-Le Royer, B., Mullard, M., Brown, H. K., Verrecchia, F., & Heymann, D. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.01.003 · Cited by 14

Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity.

Levi‐Schaffer, F., & Bar‐Shavit, Z. (1990) · PubMed Central · Cited by 11

Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect

Kiany, S., & Gordon, N. B. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3684-7_24 · Cited by 10

Proteoglycans and Osteolysis

Baud’huin, M., Charrier, C., Bougras-Cartron, G., Brion, R., Lézot, F., Padrines, M., & Heymann, D. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-498-8_21 · Cited by 7

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660

Molecular Biology of Osteosarcoma

Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343

Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma

Xiao, B., Liu, L., Li, A., Xiang, C., Wang, P., Li, H., & Xiao, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.607622 · Cited by 330

Sarcoma treatment in the era of molecular medicine

Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 300

Immune Environment and Osteosarcoma

Heymann, M., & Heymann, D. (2017) · InTech eBooks · doi:10.5772/67448 · Cited by 8

CXCL6-CXCR2 axis-mediated PD-L2+ mast cell accumulation shapes the immunosuppressive microenvironment in osteosarcoma

Wang, C., Lei, Z., Zhang, C., & Hu, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34290 · Cited by 6

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response

Cascini, C., & Chiodoni, C. (2021) · Cells · doi:10.3390/cells10071668 · Cited by 63

Abstract 4973: The immunosuppressive tumor microenvironment of metastatic osteosarcoma inhibits the cytotoxic effect of tumor-infiltrating lymphocytes

Ligon, J. A., Oke, T. F., Choi, W., Fong, M. H. Y., Levin, A. S., Rhee, D. S., Morris, C. D., Siegel, N. M., Hsieu, E. H., Meyer, C. F., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4973

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

Zhu, T., Han, J., Liu, Y., Cai, Z., Sun, W. Y., Hua, Y., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907550 · Cited by 113